Profile
Lead is a dense metal long associated with radiation shielding, but it also forms radioisotopes valuable in medicine. Lead-203 is a synthetic radioisotope produced for imaging, with a half-life of about 52 hours.
Lead-203 decays by electron capture to stable thallium-203, emitting a gamma photon well matched to SPECT imaging, and crucially it leaves no radioactive daughters, which keeps dosimetry calculations clean. Its half-life is long enough to allow extended imaging to gather the data needed for treatment planning.
Lead-203 is used chiefly as the imaging half of a matched theranostic pair with lead-212, used in targeted alpha therapy. Because the two are chemically identical, lead-203 imaging predicts almost exactly how a lead-212 therapy will behave in the body, enabling patient selection, dosimetry, and personalised treatment planning.
Lead-203 is produced via proton irradiation of an enriched thallium-203 target. It requires a high current and costly enriched target material, and few facilities currently produce it, which constrains the wider roll-out of lead-based theranostics.
StandardX is developing accelerator-based production to supply lead-203, unlocking its potential as a theranostic pair with lead-212.